PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PR Newswire•08/10/2026•12:12 ET
0
Key Highlights
- ➤Pacira buyout offers $36.50 per share in cash
- ➤Proposed transaction carries aggregate equity value of $1.65 billion
- ➤Ademi investigates whether exchange ratio reflects Pacira’s value and prospects
- ➤Investigation examines insider change-of-control benefits
- ➤Termination penalty may discourage competing superior proposals
Expert Statements
Guri Ademi, Attorney at Ademi LLP
“Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction.”
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC. PR Newswire
PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers
Get started
Create a free account to read the full story.